A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis on Background of Cyclophosphamide or Rituximab Treatment

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis on Background of Cyclophosphamide or Rituximab Treatment

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs Avacopan (Primary) ; Prednisone
  • Indications Anti-neutrophil cytoplasmic antibody-associated vasculitis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CLEAR
  • Sponsors ChemoCentryx
  • Most Recent Events

    • 01 Sep 2017 Results assessing safety and efficacy of ccx168 in subjects with anti-neutrophil cytoplasmic antibody (anca)-associated vasculitis on background of cyclophosphamide or rituximab treatment, were published in the Journal of the American Society of Nephrology.
    • 10 May 2017 Results from this trial have been published in the Journal of American Society of Nephrology (JASN), according to a ChemoCentryx media release.
    • 07 Nov 2016 Accoridng to ChemoCentryx media release, positive results will be presented at the American Society of Nephrology (ASN) Kidney Week 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top